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Combined genetic approaches yield 
a 48% diagnostic rate in a large 
cohort of French hearing-impaired 
patients
D. Baux  1, C. Vaché1, C. Blanchet2,3, M. Willems4, C. Baudoin1, M. Moclyn1, V. Faugère1,  
R. Touraine5, B. Isidor6, D. Dupin-Deguine7,8, M. Nizon6, M. Vincent6, S. Mercier6, C. Calais9,  
G. García-García10, Z. Azher10, L. Lambert11, Y. Perdomo-Trujillo12, F. Giuliano13, M. Claustres1,10, 
M. Koenig1,10, M. Mondain2,3 & A. F. Roux1,10
Hearing loss is the most common sensory disorder and because of its high genetic heterogeneity, 
implementation of Massively Parallel Sequencing (MPS) in diagnostic laboratories is greatly improving 
the possibilities of offering optimal care to patients. We present the results of a two-year period 
of molecular diagnosis that included 207 French families referred for non-syndromic hearing loss. 
Our multi-step strategy involved (i) DFNB1 locus analysis, (ii) MPS of 74 genes, and (iii) additional 
approaches including Copy Number Variations, in silico analyses, minigene studies coupled when 
appropriate with complete gene sequencing, and a specific assay for STRC. This comprehensive 
screening yielded an overall diagnostic rate of 48%, equally distributed between DFNB1 (24%) and the 
other genes (24%). Pathogenic genotypes were identified in 19 different genes, with a high prevalence 
of GJB2, STRC, MYO15A, OTOF, TMC1, MYO7A and USH2A. Involvement of an Usher gene was reported 
in 16% of the genotyped cohort. Four de novo variants were identified. This study highlights the need to 
develop several molecular approaches for efficient molecular diagnosis of hearing loss, as this is crucial 
for genetic counselling, audiological rehabilitation and the detection of syndromic forms.
Hearing loss (HL) is the most common congenital sensory impairment in humans, and it affects approximately 
1 in 600 newborns1. It is estimated that half of the cases have a genetic origin. HL can be non-syndromic (NSHL) 
and not associated with other clinical signs, or it can present as one of the symptoms in syndromic forms. In 
addition, some non-syndromic forms can evolve to syndromic forms later in life and are then defined as NSHL 
mimics2. The most common example is Usher syndrome (USH), which alters hearing and in some cases balance 
early in life, whereas it is only after the first decade that clinical signs of retinitis pigmentosa (RP) will affect the 
patient’s vision3.
Over 100 genes have been associated with NSHL and more still with syndromic HL4. Simultaneous screening 
of multiple genes is now possible with the advent of massively parallel sequencing (MPS). This approach offers 
the possibility of identifying the aetiology of the HL and thus providing proper genetic counselling to the fam-
ilies. Gene testing also impacts the clinical management of patients, as identifying the pathogenic alterations 
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in syndromic genes of patients referred for NSHL will require a change or adaptation in care, as in the case of 
Usher syndrome5. Genetic findings can also indicate the need for additional clinical evaluation that may detect 
subtle syndromic features not necessarily related to the associated syndrome6. MPS improves diagnostic rates7–9. 
Although several approaches can be used, i.e. exome or gene panels, the latter have thus far shown the best 
compromise between the mutation detected rate and cost2. Studies of large cohorts of different origins have high-
lighted that the mutation detection rate depends on clinical characteristics and ethnicity2,9. Yet no data on the 
prevalence of HL genes and positive rates for diagnostic purposes are available for French patients. We have 
therefore tested a gene-panel approach over a two-year recruiting period for 207 families referred for NSHL from 
14 centres distributed all over France. We present in this study an efficient decision-making process that identifies 
the genetic HL aetiology in 48% of patients.
Results
We analysed a total of 207 index cases over a two-year period following the decision-making tree presented below.
Decision-making tree. Analyses were performed following the tree presented on Fig. 1 (and Supplementary 
Table 1 and Supplementary Figure 1).
DFNB1 analysis was performed for all cases with the exception of those patients presenting with a family 
history of dominant transmission. Although the GJB2 and GJB6 genes are included in the panel, DFNB1 locus 
screening can be performed at reduced cost with a fast turn-around time. Patients with suspicion of Pendred/
DFNB4 disease underwent the same strategy, even though SLC26A4 can be prioritized according to scan data.
DFNB1 genotypes. Fifty-five patients were identified with pathogenic DFNB1 variants (Supplementary 
Tables 2 and 3). Six patients carrying a single pathogenic variant were further analysed on the gene panel. Patient 
S1760, who was homozygous for the p.Met34Thr variant, was also included for further studies because the clinical 
data were not coherent with the identified genotype (profound HL and enlarged vestibular aqueduct: EVA).
The 49 DFNB1 pathogenic genotypes included 20 different variants: although c.35delG represented 58% 
(57/98) of the pathogenic alleles, genetic heterogeneity was notable as most of the other variants were encoun-
tered only once or twice.
Other NSHL genotypes. In 50 additional patients, pathogenic genotypes were identified in 18 different 
genes using MPS strategy (Supplementary Table 2). The data were categorized according to genotypes identified 
in truly non-syndromic genes and in those of the NSHL mimics (i.e. USH genes).
STRC pathogenic genotypes were identified in nine patients presenting with mild to moderate HL. Of these 18 
mutant alleles, 12 consisted of large deletions of the gene. Although it was not possible to characterize the deletion 
breakpoints with our approach, we identified deletions of different sizes. The most frequent type encompassed 
the entire STRC gene and its 5′ sequence (c.(?_−78)_(*109_?)del), whereas the others maintained the 5′ end of 
the gene.
Patient S1537 was first identified as a heterozygous carrier of two alterations, a short deletion in intron 23 
(c.4545+2_4545+6del) and a potential copy number variation (CNV) in exon 28. However, visual inspection of 
the aligned sequence reads using the Integrative Genomics Viewer (IGV) highlighted a reduced depth of cover-
age of STRC-exon 28 associated with an increased depth of ψSTRC-exon 28 reads, in comparison with control 
(Supplementary Figure 2). Therefore, this CNV was more likely to be a software alignment artefact. Sanger anal-
ysis with STRC-specific long-range PCR followed by nested PCR (LR/nested PCR) that was focused on exon 28 
then identified the heterozygous substitution c.5125A > G in this patient S1537. This variant was already reported 
as pathogenic by Vona et al.10 and corresponds to an existing divergent nucleotide in the pseudogene sequence, 
explaining the misalignment of sequence reads observed with MPS technology.
IGV analyses were also conducted for S1511 and S1516, both of whom presented with moderate HL and car-
ried a heterozygous deletion encompassing the STRC gene. In both cases, a substitution in intron 11 was identi-
fied by visual inspection (c.3100-2A > T for S1511 and c.3100-18G > A for S1516). Results of the LR/nested PCRs 
confirmed the STRC localization of the variants and minigene assays revealed in both cases complete skipping of 
exon 12, resulting in the loss of 13 amino acids (Fig. 2A).
MYO15A, OTOF and TMC1 mutations were also identified in four, three and two patients, respectively. All 
identified mutations were associated with severe to profound HL.
All together more than a third (18/50) of the patients carrying a pathogenic genotype detected by MPS screen-
ing carried mutations in one of the four following genes: STRC, MYO15A, OTOF and TMC1.
Variants in rarely involved genes were also identified, such as the de novo c.2880G > A alteration in TJP2 
(patient S1324). Interestingly, this variant, located at the last nucleotide of exon 19, was not predicted to alter the 
protein sequence; the MaxEnt algorithm predicted a potential impact on splicing. Our minigene analysis con-
firmed that c.2880G > A indeed led to skipping of in-frame exon 19, which resulted in the deletion of amino acid 
residues 890–960 in the protein (Fig. 2B).
Pathogenic genotypes in Usher genes. The 10 genes responsible for USH were included in our design. 
Sixteen of the 99 patients carried a pathogenic genotype in an Usher gene, the most frequent genes being MYO7A 
and USH2A in five and four patients, respectively. All patients, with the exception of two carrying mutations in 
MYO7A, were under 15 years and had been referred for NSHL, which is consistent with the onset of RP after the 
first decade.
Interestingly, MPS analysis on patient S1679 revealed a single USH2A heterozygous c.4645C > T nonsense 
variant. According to our diagnostic strategy, USH2A-whole-gene screening was then performed and detected a 
deep intronic substitution likely to affect splicing. This variation, c.14134-3169A > G in intron 64, predicted the 
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creation of a strong donor splice site (MaxEntScan score: 7.64) potentially leading to a new pseudoexon (PE) acti-
vation. Minigene assay confirmed the pathogenic effect of this intronic variant on the splicing process and defined 
the size of the inserted pseudoexon PE64 (Fig. 2C). The latter, composed of 52 nucleotides, carried a premature 
termination codon (PTC) leading to a truncated protein if synthetized.
Additional pathogenic variants. Ten of the 50 patients genotyped by MPS carried an additional patho-
genic variant in another gene (Supplementary Table 2). Four corresponded to the GJB2 heterozygotes initially 
screened at the DFNB1 locus. Unsurprisingly, one of them was a c.35delG heterozygote and two other patients 
carried the p.(Met34Thr) alteration. This reflects the carrier frequencies of these two variants in the general pop-
ulation11. Two of the patients were MYO15A heterozygotes and another carried a deletion in STRC; again, these 
being two frequently involved genes in NSHL.
Figure 1. Decision-making tree for molecular diagnosis of isolated hearing loss. *74 HL genes, see 
Supplementary Table 1. **See Supplementary Figure 1. $CNV: Copy Number Variation, deletions/duplications 
involving at least one exon and occurring in an isoform involved in hearing. $$aCGH: array Comparative 
Genomic Hybridization; QMPSF: Quantitative Multiplex PCR of Short Fluorescent fragments. All SNVs and 
small indels are confirmed by Sanger sequencing or long-range PCRs followed by Sanger sequencing for STRC 
variants.
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3D analysis. In order to better characterize the missense variants, we performed a structural analysis using 
3D modelling. This approach requires the availability of a crystallographic structure or a reliable model. For 
example, patient S1542 carried the POU4F3 p.(Phe322Ser) variant and the structure showed a localization 
in helix 3 of the homeodomain in the model Oct-1 (POU2F1) protein. This helix directly binds DNA and the 
highly conserved Phe is part of the hydrophobic core involving helices 1 and 2 that stabilizes the helix-turn-helix 
Figure 2. Minigene analysis to assess the impact of variants on splicing. Full-length gels showing: (A) 
STRC variants c.3100-2 A > T and c.3100-18 G > A leading to complete skipping of exon 12. The lower band 
observed for the wild-type construction may be due to an artefact of the minigene system or alternative 
splicing of exon 12; (B) TJP2 c.2880G > A leading to complete skipping of exon 19; (C) USH2A variant 
c.14134-3169 A > G leading to the inclusion of a pseudoexon between native exons 63 and 64 (PE64); bold: 
termination codon.
www.nature.com/scientificreports/
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conformation of the domain and allows the binding with DNA. Replacement of Phe with the small polar Ser 
would very likely destabilize the region and might impact DNA binding (Fig. 3). Familial segregation of this var-
iant was further confirmed over a three-generation family that included six affected patients.
Discussion
Diagnostic rate. In order to establish an unbiased diagnostic rate, we included all patients referred for NSHL 
over a two-year period, without selecting the degree of HL or familial history. Following the described strategy, we 
were able to unambiguously genotype 48% of the patients (Fig. 4). Use of MPS drastically improved the diagnos-
tic rate, by doubling the number of patients diagnosed with a confirmed genetic origin in our cohort. Nineteen 
different genes were causally implicated, but among them only five contributed to 71% of the cases: GJB2 (DFNB1 
locus), STRC, MYO7A, MYO15A and USH2A (Fig. 4).
Two other studies testing large cohorts with different HL gene panels have recently reported diagnostic rates 
varying from 327 to 56%12. However, in the latter, the high positive rate was explained by an enrichment of famil-
ial cases. Sloan-Heggen et al. provided data on the largest cohort (n = 1,119) with an overall rate of 39%. They 
showed that the positive rate varies greatly with degree of HL, inheritance of HL and ethnicity2. Comparing rates 
across different studies is difficult as many different parameters can interfere, from the composition of the cohort 
to the genes analysed.
One hundred and eight patients remained undiagnosed with no or a single identified pathogenic variant. For 
an unknown proportion of these patients, the HL is not of genetic origin. However, to improve the diagnostic 
rate of genetic cases, additional genes mimicking NSHL and involved in syndromic forms could be included in 
the panel2. Recently, Abou Tayoun et al. suggested that only genes with strong gene-disease association criteria 
should be included in diagnostics, and these authors provided a valuable core panel13. However, if genes with 
weak gene-disease association are not included, additional clues that a gene is indeed involved in HL might be 
missed. As an example, not including TJP2 would have missed the diagnosis for patient S1324.
Figure 3. 3D analysis of POU4F3 p.(Phe322Ser) using homolog Oct-1 PDB structure 1E3O. The homeodomain 
directly binds DNA through helix 3 and the positively charged amino acids Arg or Lys (red). The equivalent of 
Phe 322 (A, white), also located in helix 3, is involved in the hydrophobic core with helices 1 and 2 stabilizing 
the region. Introduction of a small polar amino acid (Ser, B, white) is likely to modify the hydrophobic core and 
the domain and might modify DNA binding properties of the protein.
www.nature.com/scientificreports/
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Using the gene panel approach for diagnostic purposes is still valuable as the quality remains superior to clin-
ical exome or whole exome sequencing14. Therefore, a reasonable approach would be to include HL genes as well 
as candidates in a larger gene panel and to define a core diagnostic list following recommendations13. Diagnosis 
would be established quite confidently for genes included in the core list, whereas interpretation would be more 
cautious for the other genes.
STRC analysis pitfalls. In accordance with other studies2,7, our results show that STRC was prone to large 
deletions and was clearly the second most frequent gene to be involved in NSHL. Tandem repeats are genomic 
features prone to instability and, as expected, large CNVs were the major mutational event for the STRC gene, 
with an estimated heterozygous deletion frequency of 1% to 1.6%15. In line with this high carrier rate, S1689 
was identified as a heterozygous carrier of a STRC deletion (Supplementary Table 3). STRC was most likely not 
involved as this patient presented with profound hearing loss.
Overall, because of the high sequence homology between STRC and ψSTRC, specific approaches need to be 
developed to detect the large rearrangements as well as the point mutations that can be masked by the ψSTRC 
sequences.
De novo occurrence of variants. De novo variants were observed in several cases involving both DFNA or 
DFNB/USH genes. The ACTG1 variant (c.434C > T, p.(Ser145Phe)) arose de novo in S1572. This variant was con-
firmed to be absent in both parent samples. Mutations in ACTG1 can be associated with either Baraister-Winter 
syndrome16 or NSHL17. In the present case, the young patient presented only NSHL with normal facial appear-
ance, although MRI was not performed. At birth, otoacoustic emissions (OAEs) were recordable and hearing 
loss was moderate but evolved into profound within three years. De novo variants of this gene have already been 
described in several Baraister-Winter cases18.
A de novo TJP2 variant (c.2880G > A) was also identified in patient S1324. Minigene analysis demonstrated 
an effect on the splicing process (Fig. 2B), and the implication of TJP2 in NSHL remains questionable. The pro-
gression of HL was noted over 15 years, altering mainly high frequencies. The de novo occurrence of the variant 
together with the alteration in TJP2 splicing reinforces the hypothesis that this gene is indeed involved in NSHL.
Familial segregation performed for S1759 revealed that neither parent was a carrier of the TECTA p.(Pro-
2079Leu) variant, suggesting a de novo occurrence. The residue Pro was perfectly conserved among 89 orthologs 
(UCSC MultiZ alignment, not shown) and was located within a highly-conserved region of the protein. The 
patient presented with a moderate congenital HL with a flat configuration; as he was under 2 years of age, an 
evolution in HL cannot be excluded.
Figure 4. Diagnostic rates of the French NSHL cohort. After DFNB1 screening, 158 patients underwent MPS 
and pathogenic genotypes could be defined for 50 of them, involving 18 different genes.
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Last, patient S701 was found to carry two alterations in the CDH23 gene. But as the c.6254-2A > G variant 
arose de novo, it was not possible to determine whether the two alterations are in trans. At this date, a question 
remains about a possible Usher syndrome.
All patients were initially sent for isolated, sporadic NSHL and these findings pinpoint the importance of 
systematic segregation analyses as identification of de novo variants in dominant forms of NSHL will have a direct 
impact on transmission risk and further genetic counselling.
Correlating genotypes with phenotypes for NSHL. This study confirms that TMPRSS3 is involved in 
progressive HL. The patient audiograms had a characteristic ski-slope configuration as previously shown19. The 
MYO15A and TMC1 mutations are mainly associated with severe to profound HL, whereas STRC alterations lead 
to mild to moderate hearing loss. All patients carrying OTOF mutations presented with profound HL. Most of 
the variants led to PTC and loss of functional protein. Recent data suggest that some missense variants can act as 
hypomorphic alleles and can be associated with moderate HL20. It is likely that in the future we will also extend 
the phenotypic spectrum associated with OTOF variants.
Questions linked to the identification of pathogenic genotypes in genes mimicking NSHL. We 
identified a USH pathogenic genotype in 16% of the patients. All patients were initially referred for NSHL. After 
genotyping, two groups should be distinguished based on age, i.e. those with NSHL mimics and those with true 
NSHL.
CDH23, MYO7A and USH1C have long been known to be involved in USH as well as non-syndromic hear-
ing loss21–23. Therefore, it is possible that not all patients with mutations in these genes will develop a typical 
Usher syndrome. For example, patient S1692 is 27 years old and the electroretinogram (ERG) performed after 
the molecular results was found to be subnormal. Consequently, this patient is not expected to develop a typical 
Usher syndrome and signs of RP may remain very subtle throughout his lifetime. Similarly, S1741, S1763 and 
S1799 underwent further clinical examination after the molecular results and it is suspected that all will develop 
Usher syndrome. The awareness of future development of RP will have an impact on audiological rehabilitation 
and the genetic counselling for the families. In several cases, prenatal diagnosis could thus be offered for the 
next pregnancies. Last, patients carrying USH1C (S1536, S1707), USH2A (S1682, S1679, S1752 and S1786) and 
ADGRV1 variants (S1338 and S1601) were referred to ophthalmology clinics in order to establish their visual 
function.
Additional tools are required for optimized diagnostic service. In this study, we provide a rather 
comprehensive approach through the development of interpretation tools. Indeed, when possible, 3D analysis 
can provide additional clues to classify a variant, which is shown with the example of the POU4F3 p.(Phe322Ser) 
variant (Fig. 3).
An additional step for assessing missense pathogenicity would be to perform in vitro functional tests, whose 
feasibility has been demonstrated for genes such as SLC26A424.
We previously showed the usefulness of integrating minigene analysis for detailed study of the consequences 
of predicted splicing alterations25,26. Again, four variants identified in this cohort could be confirmed as affecting 
splicing by minigene analysis (Fig. 2).
In addition, because several USH2A deep intronic mutations have already been identified26,27, we recommend 
performing either transcript analysis or whole USH2A gene sequencing for patients carrying a single USH2A 
pathogenic variant. This allowed the identification of a novel deep intronic mutation in intron 64, leading to a new 
PE insertion. This mutation has since been identified in another patient presenting with Usher type 2 (unpub-
lished results). All together, this is the fifth deep intronic mutation resulting in PE insertion identified in USH2A, 
thus confirming the particularly high rate of this type of alteration in the most frequent USH gene.
In conclusion, this study based on the genetic screening of 207 patients referred for NSHL shows that MPS 
clearly improves the molecular diagnosis of NSHL in the French population, as already shown in other popula-
tions. However, this diagnostic rate of 48% was achieved using MPS plus other approaches aimed at characteriz-
ing the impact of variants or confirming their actual existence (in silico and minigenes studies, CNVs analysis), or 
identifying them in the case of STRC variants and USH2A deep intronic variants (customized whole gene screen-
ing). In addition, a high proportion of our cohort presented with pathogenic genotypes in USH genes, which 
should thus definitely be included in NSHL screening as their involvement immediately modifies the medical care 
for both patients and their families.
Methods
Patient recruitment. All patients included in this study were referred from medical genetics or ENT 
departments for apparent NSHL. They or their parents responded to a clinical questionnaire for family history 
and audiograms were performed to evaluate their degree of HL.
Informed consent to genetic testing was obtained from adult probands or parents in the case of minors after 
explanation of the nature and its possible implications for the patient and his family. This study was performed in 
accordance with the French law on bioethics: ‘loi de bioéthique’, revised 7 July 2011, number 2011-814. The exper-
imental protocol is approved by the Montpellier University Hospital (CHU Montpellier) as part of the molecular 
diagnostic activity. The authorization number given by the Agence Régionale de la Santé (ARS) is LR/2013-N°190. 
Nominative licensing in the name of Dr. Roux was delivered by Agence de la Biomédecine.
Hearing loss assessment. Audiometric data were collected from the various departments and obtained 
using calibrated audiometers according to the International Organization for Standardization ISO28. In adults 
and children of at least 6 years old, bilateral air and bone conduction hearing thresholds (dB HL) were obtained 
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for 0.25, 0.5, 1, 2, 4 and 8 kHz frequencies. For young children unable to undergo bilateral evaluation, open-field 
air and bone conduction thresholds were assessed using age-appropriate procedures (behavioural observation 
audiometry, visual reinforced audiometry or play audiometry). An electrophysiological assessment completed the 
audiological evaluation if necessary (i.e. auditory brainstem response thresholds, auditory steady state response, 
acoustic otoemission). Data from universal newborn screening were collected for the youngest patients.
Hearing loss degree was analysed according to the International Bureau for Audiophonology audiometric 
classification (https://www.biap.org/en/recommandations/recommendations/tc-02-classification/213-rec-02
-1-en-audiometric-classification-of-hearing-impairments/file), whereas other phenotype features were analysed 
according to the recommendations for the description of non-syndromic hearing loss29. Sensorineural hearing 
loss was found in all cases.
DFNB1 locus screening. The screening was performed as recommended by the EMQN DFNB1 guidelines30 
and included Sanger sequencing of GJB2 exons 1 and 2 and their flanking intronic regions and multiplex PCR 
as designed by del Castillo et al.31 to detect the two large deletions encompassing part of the GJB6 gene, del(G-
JB6-D13S1830) and del(GJB6-D13S1854).
Sequences were compared with the reference sequence using the Seqscape 2.5 software.
Gene-panel sequencing and bioinformatics. All patients underwent MPS gene-panel testing if DFNB1 
locus screening showed no evidence of a pathogenic genotype (Fig. 1). Two panels were used. The first one 
included 65 genes and was designed with Illumina® Nextera Rapid Capture Custom Enrichment technology. An 
updated design of 74 DFN genes was performed and used for most of the patients (Supplementary Table 1) with 
NimbleGen SeqCap EZ Choice technology. All patients negative for the first panel were analysed with the updated 
74 NSHL gene panel. The pros and cons of both enrichment technologies are detailed in32. Both designs were tar-
geting the exons referenced in RefSeq or Ensembl (coding and non-coding) with 50 bp surroundings. Sequencing 
was performed on either an Illumina MiSeq instrument (using version 2 chemistry) or an Illumina MiniSeq 
system. As the two instruments have a similar output, the number of samples per run was the same (12 samples). 
The secondary analysis (mainly alignment and variant calling) was performed using the commercial software 
MiSeqReporter (v2.5) for the MiSeq runs and LocalRunManager (v1.3.1) for the MiniSeq runs, these workflows 
being very similar. Variant Calling Files (VCFs) were automatically included in our in-house database system 
(USHVaM2), which also handled variant annotation. In addition, when the pathogenic genotype was unclear, 
the samples were re-analysed using an in-house pipeline (Nenufaar, https://github.com/mobidic/nenufaar), 
which performed the secondary analysis and annotation of the variants. In particular, Nenufaar uses more recent 
software than the commercial pipelines and is better at retrieving small indels. Last, variants of interest were all 
confirmed by Sanger sequencing.
When STRC variants were identified, confirmation was performed by nested PCR. Briefly, STRC nested PCRs 
consist of a first long-range amplification (LR-PCR) excluding the ψSTRC pseudogene followed by nested ampli-
fications targeting exons of interest and exon 20 to confirm pseudogene exclusion. The GoTaqLong PCR Promega 
kit (Promega) LR-PCR was used for LR-PCR according to the manufacturer’s recommendations and with prim-
ers described lesewhere33. LR-PCR products were diluted 1:1000 and then used for the nested PCRs. Primer 
sequences and reaction conditions for nested PCR are available on request.
Whole USH2A sequencing. Whole USH2A sequencing was performed for S1679 as already described by 
Liquori et al.26. Following the defined thresholds, a single variant susceptible to alter splicing was tested by mini-
gene analysis.
Detection of copy number variants (CNVs). In order to highlight the potential CNVs, which are not 
retrieved by the described pipelines, we used an in-house spreadsheet that computes the inter-sample normalized 
depth of coverage per exon in a given run. Potential CNVs were validated by array CGH using a Sure Print G3 
CGH personal 4*180K custom design for 26 HL genes labelled with the SureTag Complete labelling kit. The array 
was analysed on an Agilent DNA microarray scanner C. For the remaining genes, quantitative multiplex PCR of 
short fluorescent fragments (QMPSF) designed with specific labelled primers was used when necessary.
In particular, suspected large deletions of STRC were confirmed by QMPSF using four sets of prim-
ers targeting specific STRC sequences (5′ sequence: forward: 5′-TAGCTGGGATTACAGGTGC-3′, reverse: 
FAM5′-CATTCACTACCGGGCGTAG; 3′ sequence: forward: 5′-GTTGCACCAGCTCCACCTAAG-3′, 
reverse: FAM5′-TGAGATCCTAAGGGATTAGGAC; Intron 16: forward: 5′-AGTGTTTGGTCCATTGTAA 
AGTC-3′, reverse: FAM5′-CCATTGTTCTTCTAATGTGGGTG; Intron 22: forward: 5′-TGGGTTCTACAT 
GTGCTCTTCC-3′, reverse: FAM5′-TACAGAATTCTAGAACTACAAGAGG-3′) and one additional set screen-
ing exon 18 of the USH2A gene, as a control (forward: 5′-AAGTAACCCCTTTGTCTGATGAGT-3′, reverse: 
FAM5′-AAGACTCTGAACTCATACTTGGTG-3′).
For potential short STRC CNVs, binary alignment map (BAM) files were loaded into the integrative genomics 
viewer (IGV) software (v2.3.55)34 in order to globally inspect the aligned sequence reads between the STRC gene 
and the ψSTRC pseudogene.
Point mutations were validated with a long-range PCR assay specific to the STRC gene (specificity of the 
amplification was ascertained by the absence of the divergent c.4057C > T base pair) followed by nested PCRs.
Variant classification. Variants were classified using a fully described method35 (Supplementary Figure 1) 
that includes six classes from neutral to pathogenic and four classes of variants of unknown clinical significance. 
Variants predicting the inclusion of a PTC or located at canonical splicing positions (−2,−1, +1, +2 positions 
around exons) of isoforms described in pathology were considered a priori pathogenic. The main characteristics 
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for missense classification were the familial segregation of the variant, its frequency in public databases, evolu-
tionary conservation throughout orthologs and paralogs (domain conservation) and, when available, the impact 
on the 3D structure.
3D analysis of NP_002691.1: p.(Phe322Ser) was performed using human Oct-1 homeodomain encoded by 
POU2F1 (Protein Data Bank ID: 1E3O) binding DNA as the model. 1E3O shares 56% amino acids identity with 
pou4f3 through residues 182–332 and 66% (12/18) for residues surrounding pou4f3 position 322 in helix 3 (res-
idues 141–158). The pictures were built using the PyMOL software (The PyMOL Molecular Graphics System, 
Version 1.8 Schrödinger, LLC).
The potential impact on splicing for rare missense, isosemantic and intronic variants was also assessed using 
a local implementation of the MaxEnt algorithm36 and, when available, using dbscSNV results37. Minigene anal-
ysis was performed to experimentally verify the impact of selected variants on the splicing process, as described 
alsewhere38.
Data Availability. All DNA variants identified during the course of this study have been deposited into the 
public LOVD3 shared genetic database: https://databases.lovd.nl/shared/ or the public LOVD2 “Retinal and hear-
ing impairment genetic mutation database” (https://grenada.lumc.nl/LOVD2/Usher_montpellier/).
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